Monte Rosa Therapeutics Past Earnings Performance
Past criteria checks 0/6
Monte Rosa Therapeutics's earnings have been declining at an average annual rate of -23.7%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been growing at an average rate of 171.5% per year.
Key information
-23.7%
Earnings growth rate
101.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 171.5% |
Return on equity | -88.7% |
Net Margin | -12,714.5% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth
Mar 20Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation
Sep 29Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?
May 01We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate
Jan 16We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Oct 01Monte Rosa Therapeutics rises 9% after FDA clears application for human trial of lung cancer treatment
Sep 06We're Hopeful That Monte Rosa Therapeutics (NASDAQ:GLUE) Will Use Its Cash Wisely
Jun 17We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Mar 04We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn
Sep 24Revenue & Expenses Breakdown
How Monte Rosa Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 1 | -135 | 41 | 103 |
31 Dec 23 | 0 | -135 | 40 | 103 |
30 Sep 23 | 0 | -133 | 46 | 95 |
30 Jun 23 | 0 | -125 | 42 | 90 |
31 Mar 23 | 0 | -117 | 38 | 60 |
31 Dec 22 | 0 | -109 | 35 | 77 |
30 Sep 22 | 0 | -101 | 25 | 78 |
30 Jun 22 | 0 | -94 | 23 | 72 |
31 Mar 22 | 0 | -86 | 21 | 65 |
31 Dec 21 | 0 | -74 | 16 | 57 |
30 Sep 21 | 0 | -70 | 13 | 49 |
30 Jun 21 | 0 | -57 | 9 | 39 |
31 Mar 21 | 0 | -44 | 6 | 29 |
31 Dec 20 | 0 | -36 | 4 | 24 |
Quality Earnings: GLUE is currently unprofitable.
Growing Profit Margin: GLUE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLUE is unprofitable, and losses have increased over the past 5 years at a rate of 23.7% per year.
Accelerating Growth: Unable to compare GLUE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLUE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: GLUE has a negative Return on Equity (-88.7%), as it is currently unprofitable.